docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracil
Phase 3Recruiting 0 views this week 0 watching⚡ Active
Interest: 47/100
47
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Nasopharyngeal Carcinoma
Conditions
Nasopharyngeal Carcinoma
Trial Timeline
Jun 1, 2018 → Jun 1, 2026
NCT ID
NCT03503136About docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracil
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracil is a phase 3 stage product being developed by Sun Pharmaceutical for Nasopharyngeal Carcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03503136. Target conditions include Nasopharyngeal Carcinoma.
What happened to similar drugs?
0 of 12 similar drugs in Nasopharyngeal Carcinoma were approved
Approved (0) Terminated (0) Active (12)
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
Hype Score Breakdown
Clinical
17
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03503136 | Phase 3 | Recruiting |
Competing Products
20 competing products in Nasopharyngeal Carcinoma